Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping

MLA

Papaxoinis, G.Kotoula, V.Giannoulatou, E.Koliou, G. A.Karavasilis, V.Lakis, S.Koureas, A.Bobos, M.Chalaralambous, E.Daskalaki, E.Chatzopoulos, K.Tsironis, G.Pazarli, E.Chrisafi, S.Samantas, E.Kaklamanos, I. G.Varthalitis, I.Konstantara, A.Syrigos, K. N.Pentheroudakis, G.Pectasides, D.Fountzilas, G. Phase II Study of Panitumumab Combined with Capecitabine and Oxaliplatin as First-Line Treatment in Metastatic Colorectal Cancer Patients: Clinical Results Including Extended Tumor Genotyping. Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2127..752c98c8a237b1fb977312a706756b32&authtype=sso&custid=ns315887.

APA

Papaxoinis, G. K. V. G. E. K. G.-A. K. V. L. S. K. A. B. M. C. E. D. E. C. K. T. G. P. E. C. S. S. E. K. I. G. V. I. K. A. S. K. N. P. G. P. D. F. G. (2018). Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.

Chicago

Papaxoinis, G. Kotoula, V. Giannoulatou, E. Koliou, G.-A. Karavasilis, V. Lakis, S. Koureas, A. Bobos, M. Chalaralambous, E. Daskalaki, E. Chatzopoulos, K. Tsironis, G. Pazarli, E. Chrisafi, S. Samantas, E. Kaklamanos, I.G. Varthalitis, I. Konstantara, A. Syrigos, K.N. Pentheroudakis, G. Pectasides, D. Fountzilas, G. 2018. “Phase II Study of Panitumumab Combined with Capecitabine and Oxaliplatin as First-Line Treatment in Metastatic Colorectal Cancer Patients: Clinical Results Including Extended Tumor Genotyping,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2127..752c98c8a237b1fb977312a706756b32&authtype=sso&custid=ns315887.